UroGen Pharma Ltd. (URGN)

Market Cap	193.73M
Revenue (ttm)	64.36M
Net Income (ttm)	-109.78M
Shares Out	23.09M
EPS (ttm)	-4.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,137
Open	8.29
Previous Close	8.36
Day's Range	8.05 - 8.55
52-Week Range	4.85 - 12.63
Beta	0.76
Analysts	Buy
Price Target	23.87 (+184.51%)
Earnings Date	May 8, 2023

About URGN

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2017
• Employees: 195
• Stock Exchange: NASDAQ
• Ticker Symbol: URGN

Financial Performance

In 2022, UroGen Pharma's revenue was $64.36 million, an increase of 33.96% compared to the previous year's $48.04 million. Losses were -$109.78 million, -0.94% less than in 2021.

Analyst Forecast

According to 12 analysts, the average rating for URGN stock is "Buy." The 12-month stock price forecast is $23.87, which is an increase of 184.51% from the latest price.

Price Target

$23.87

(184.51% upside)

Analyst Consensus: Buy